GlobeNewsWire · PBLS · October 24, 2026

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Get the app for more

Explore stock news, insights and company research.